Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer Purpose New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. Methods Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events. Results Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3–4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/gemcitabine-plus-nab-paclitaxel-vs-folfirinox-for-patients-with-T4WSTUsuNo
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3611-y
Publisher site
See Article on Publisher Site

Abstract

Purpose New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. Methods Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events. Results Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3–4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: May 30, 2018

References

  • Global cancer statistics 2012
    Torre, LA; Bray, F; Siegel, RL; Ferlay, J; Lortet-Tieulent, J; Jemal, A
  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Conroy, T; Desseigne, F; Ychou, M
  • Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    Hoff, D; Ervin, T; Arena, F
  • Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
    Hoff, DD; Ramanathan, RK; Borad, MJ; LAheru, DA; Smith, LS; Wood, TE; Korn, RL; Desai, N; Trieu, V; Iglesias, JL; Zhang, H; Soon-Shiong, P; Shi, T; Rajeshkumar, NV; Maitra, A; Hidalgo, M
  • Dilemma of first-line regimens in metastatic pancreatic adenocarcinoma
    Ghosn, M; Ibrahim, T; Assi, T; EI Rassy, E; Kourie, HR; Kattan, J
  • Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma
    Hashimoto, M; Hikichi, T; Suzuki, T; Tai, M; Ichii, O; Matsuhashi, N; Kita, E; Takahashi, S; Okubo, Y; Hakozaki, H; Ejiri, Y; Ohira, H
  • Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer
    Date, K; Ettelale, C; Maraveyas, A
  • Efficacy and safety of FOLFIRINOX in locally advanced pancreatic cancer. A single center experience
    Lakatos, G; Petranyi, A; Szucs, A; Nehez, L; Harsanyi, L; Hegyi, P; Bodoky, G
  • Pancreatic cancer and thromboembolic disease, 150 years after Trousseau
    Ansari, D; Ansari, D; Andersson, R; Andren-Sandberg, A
  • Phase II study FOLFIRINOX for chemotherapy-naïve Japanese
    Okusaka, T; Ikeda, M; Fukutomi, A; Ioka, T; Ohkawa, S; Isayama, H; Boku, N
  • Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
    Ueno, H; Ikeura, M; Ueno, M; Mizuno, N; Ioka, T; Omura, Y; Nakajima, TE; Furuse, J
  • Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetics analysis
    Ando, Y; Saka, H; Ando, M
  • Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial
    Burris, HA; Moore, MJ; Andersen, J; Green, MR; Rothenberg, ML; Modiano, MR; Cripps, MC; Portenoy, RK; Stomiolo, AM; Tarassoff, P; Neison, R; Dorr, FA; Stephens, CD; Hoff, DD
  • Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
    Alistar, A; Morris, BB; Desnoyer, R